Neurotransmission

Overview

Neurotransmission is the fundamental process by which neurons communicate with one another and with effector cells such as muscle fibers and gland cells. This electrochemical signaling system forms the basis of all nervous system function, from simple reflexes to complex cognition, emotional regulation, and motor control. Every thought, sensation, and movement depends on the precise orchestration of neurotransmitter synthesis, vesicle packaging, calcium-triggered exocytosis, receptor activation, and signal termination.

The human brain contains approximately 86 billion neurons, each forming an average of 7,000 synaptic connections. At any given moment, trillions of synaptic events are occurring simultaneously, coordinating everything from heartbeat regulation to abstract reasoning. Disruptions in neurotransmission underlie numerous neurological and psychiatric conditions, making this process a primary target for pharmacological intervention and neuropeptide research.

The Synaptic Architecture

Chemical synapses consist of three structural components: the presynaptic terminal, the synaptic cleft, and the postsynaptic membrane. The presynaptic terminal contains mitochondria for energy production, smooth endoplasmic reticulum for calcium buffering, and clusters of synaptic vesicles loaded with neurotransmitter molecules. Each vesicle contains several thousand neurotransmitter molecules held in reserve until an action potential arrives.

The synaptic cleft spans approximately 20 to 40 nanometers and contains a dense extracellular matrix rich in adhesion molecules and enzymes. This narrow gap ensures that released neurotransmitters reach their postsynaptic targets rapidly while allowing enzymatic degradation and reuptake mechanisms to terminate signaling efficiently.

Neurotransmitter Synthesis and Storage

Neurotransmitters fall into several chemical classes, each synthesized through distinct enzymatic pathways. Small-molecule transmitters such as glutamate, GABA, dopamine, serotonin, and acetylcholine are synthesized in the presynaptic terminal from amino acid precursors. Neuropeptides, by contrast, are synthesized in the cell body as larger precursor proteins that undergo post-translational processing during axonal transport.

Vesicular transporters concentrate neurotransmitters into synaptic vesicles using the proton gradient established by vesicular H+-ATPase. This active packaging process achieves concentrations several hundred times higher inside the vesicle than in the cytoplasm, creating the concentrated packets necessary for effective synaptic signaling.

Calcium-Dependent Exocytosis

When an action potential invades the presynaptic terminal, voltage-gated calcium channels open within microseconds, allowing calcium ions to flood into the terminal. This calcium influx is the critical trigger for neurotransmitter release. Calcium binds to synaptotagmin, a vesicle-associated protein that serves as the primary calcium sensor for exocytosis.

Calcium-bound synaptotagmin interacts with the SNARE complex, a molecular machine composed of synaptobrevin on the vesicle membrane and syntaxin/SNAP-25 on the plasma membrane. This interaction drives vesicle fusion with the presynaptic membrane, releasing neurotransmitter contents into the synaptic cleft in a process called exocytosis. The entire sequence from calcium entry to transmitter release takes less than one millisecond.

Postsynaptic Signal Integration

Released neurotransmitters diffuse across the synaptic cleft and bind to receptors on the postsynaptic membrane. These receptors fall into two broad categories. Ionotropic receptors are ligand-gated ion channels that open directly upon neurotransmitter binding, producing rapid postsynaptic responses within milliseconds. Metabotropic receptors are G-protein coupled receptors that activate intracellular signaling cascades through second messenger systems, producing slower but longer-lasting effects.

A single postsynaptic neuron integrates thousands of excitatory and inhibitory inputs simultaneously through spatial and temporal summation. Excitatory postsynaptic potentials, primarily mediated by glutamate acting on AMPA and NMDA receptors, depolarize the membrane toward firing threshold. Inhibitory postsynaptic potentials, mediated by GABA and glycine acting on chloride-permeable channels, hyperpolarize the membrane away from threshold. The algebraic sum of these competing influences determines whether the postsynaptic neuron fires.

Signal Termination

Rapid termination of neurotransmitter signaling is essential for precise neural coding. Three primary mechanisms accomplish this task. Enzymatic degradation breaks down neurotransmitters within the synaptic cleft; acetylcholinesterase, for example, hydrolyzes acetylcholine with extraordinary catalytic efficiency. Reuptake transporters on the presynaptic membrane actively pump neurotransmitters back into the terminal for recycling. Diffusion carries neurotransmitter molecules away from the synapse, where they are metabolized by glial cells.

Peptide Neuromodulation

Neuropeptides such as Selank, Semax, and Dihexa modulate neurotransmission through mechanisms distinct from classical transmitters. Unlike small-molecule neurotransmitters released from small clear vesicles at active zones, neuropeptides are released from large dense-core vesicles and often act through volume transmission, diffusing over greater distances to influence broader neural circuits.

Peptide neuromodulators alter synaptic efficacy by modifying receptor sensitivity, ion channel conductance, and gene expression in target neurons. BPC-157 has demonstrated neuroprotective properties in preclinical models of neurotransmitter system disruption, while DSIP (Delta Sleep-Inducing Peptide) modulates neurotransmission patterns associated with sleep-wake cycling. These modulatory actions operate on timescales of seconds to hours, providing a regulatory layer that shapes the overall tone and responsiveness of neural circuits.

Clinical Significance

Dysfunction in neurotransmission underlies a vast spectrum of neurological and psychiatric conditions. Parkinson's disease involves degeneration of dopaminergic neurons in the substantia nigra. Depression has been linked to altered serotonergic and noradrenergic transmission. Epilepsy reflects imbalances between excitatory and inhibitory neurotransmission. Myasthenia gravis results from autoimmune disruption of acetylcholine receptors at the neuromuscular junction.

Understanding neurotransmission at the molecular level has enabled the development of targeted pharmacological agents and has driven interest in peptide-based neuromodulators that may offer more selective modulation of specific neural circuits with fewer off-target effects than traditional small-molecule drugs.